These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21320292)

  • 21. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
    Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB
    Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.
    Williams NK; Lucet IS; Klinken SP; Ingley E; Rossjohn J
    J Biol Chem; 2009 Jan; 284(1):284-291. PubMed ID: 18984583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
    Levitt JM; Yamashita H; Jian W; Lerner SP; Sonpavde G
    Mol Cancer Ther; 2010 May; 9(5):1128-35. PubMed ID: 20406945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Future Oncol; 2006 Dec; 2(6):655-65. PubMed ID: 17155893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
    Lee D; Gautschi O
    Clin Lung Cancer; 2006 May; 7(6):381-4. PubMed ID: 16800962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of ER-Src axis in hormonal therapy resistance.
    Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
    Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?
    Chen Y
    Leuk Res; 2011 Jan; 35(1):27-9. PubMed ID: 20723974
    [No Abstract]   [Full Text] [Related]  

  • 29. Dasatinib.
    Lindauer M; Hochhaus A
    Recent Results Cancer Res; 2010; 184():83-102. PubMed ID: 20072833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [SRC kinases in tumor therapy].
    Dempke W; Zippel R
    Med Klin (Munich); 2010 Oct; 105(10):711-5. PubMed ID: 20981590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
    Woodman SE; Trent JC; Stemke-Hale K; Lazar AJ; Pricl S; Pavan GM; Fermeglia M; Gopal YN; Yang D; Podoloff DA; Ivan D; Kim KB; Papadopoulos N; Hwu P; Mills GB; Davies MA
    Mol Cancer Ther; 2009 Aug; 8(8):2079-85. PubMed ID: 19671763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
    Takahashi S; Miyazaki M; Okamoto I; Ito Y; Ueda K; Seriu T; Nakagawa K; Hatake K
    Cancer Sci; 2011 Nov; 102(11):2058-64. PubMed ID: 21781226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status of SRC inhibitors in solid tumor malignancies.
    Puls LN; Eadens M; Messersmith W
    Oncologist; 2011; 16(5):566-78. PubMed ID: 21521831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
    Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
    Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.
    Mayer EL; Baurain JF; Sparano J; Strauss L; Campone M; Fumoleau P; Rugo H; Awada A; Sy O; Llombart-Cussac A
    Clin Cancer Res; 2011 Nov; 17(21):6897-904. PubMed ID: 21903773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
    Johnson FM; Bekele BN; Feng L; Wistuba I; Tang XM; Tran HT; Erasmus JJ; Hwang LL; Takebe N; Blumenschein GR; Lippman SM; Stewart DJ
    J Clin Oncol; 2010 Oct; 28(30):4609-15. PubMed ID: 20855820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
    Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
    Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
    Hayette S; Chabane K; Michallet M; Michallat E; Cony-Makhoul P; Salesse S; Maguer-Satta V; Magaud JP; Nicolini FE
    Leuk Res; 2011 Jan; 35(1):38-43. PubMed ID: 20673586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
    Teng Y; Cai Y; Pi W; Gao L; Shay C
    J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
    Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.